Hodgson, Anjelica and Rhijn, Bas W. G. van and Kim, Sung Sun and Ding, Colleen and Saleeb, Rola and Vesprini, Danny and Liu, Stanley K. and Yousef, George M. and Kwast, Theodorus H. van der and Xu, Bin and Downes, Michelle R. (2020) Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations. PATHOLOGY RESEARCH AND PRACTICE, 216 (11): 153186. ISSN 0344-0338,
Full text not available from this repository. (Request a copy)Abstract
FGFR3 mutations are frequently mutually exclusive of TP53 mutations in invasive high grade urothelial carcinoma (HGUC) and p53 immunohistochemistry is often used as a surrogate for TP53 mutations. A 10 % staining cut off has been used in HGUC for designation as p53 positive or negative however, a novel contemporary method we have previously proposed (0% or 50 % abnormal vs. 1-49 % wild type) has shown significant correlation with oncologic outcome as well. We aimed to compare how a >= 10 % vs. 0 % and >= 50 % cut off p53 assessment method correlates with TP53 and FGFR3 mutation status. Tissue microarrays created from three retrospective cohorts (two cystectomy cohorts (cohort A, n = 206 and cohort B, n = 91; one T1 transurethral resection cohort (cohort C, n = 47)) were stained with p53 and scored by two blinded reviewers using both p53 scoring schemes. 50 cases from cohort A were assessed for TP53 and FGFR3 mutation status using next generation sequencing and FGFR3 mutation status was separately assessed in cohorts B and C using SNaPshot methodology. 202 (58.7 %) and 142 (41.3 %) cases showed abnormal and wild type p53 staining, respectively. Using the 10 % cut off, 254 cases were positive (73.8 %) and 90 cases were negative (26.2 %). 27 (14.4 %) and 15 (30 %) assessed cases demonstrated FGFR3 and TP53 mutations, respectively; 19/27 FGFR3 mutated showed a wild type pattern of p53 expression while 15/15 TP53 mutated tumours showed an abnormal pattern of p53 expression. There was a significant correlation between the contemporary p53 scoring scheme and TP53 and FGFR3 mutations (p < 0.0001 and p = 0.002, respectively). Improved sensitivity, specificity, positive predictive value, and negative predictive value for TP53 mutation was also seen compared to the 10 % cut off; specifically, the sensitivity and negative predictive value were 100 %. These findings might be of clinical relevance in the era of precision medicine.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | TRANSITIONAL-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR-3; GENE-MUTATIONS; PROGNOSTIC-FACTOR; ACTIVATING MUTATIONS; EXPRESSION; PATHWAYS; MARKER; TRANSFORMATION; HETEROGENEITY; Bladder cancer; Urothelial carcinoma; p53 immunohistochemistry; TP53 mutation; FGFR3 mutation |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 08 Mar 2021 09:41 |
| Last Modified: | 08 Mar 2021 09:41 |
| URI: | https://pred.uni-regensburg.de/id/eprint/43442 |
Actions (login required)
 |
View Item |
